Cost-effectiveness analysis, budget-impact modelling, pharmaceutical pricing, and value-of-medicines assessment to improve access and affordability in Ethiopia.
Economic evaluation provides the evidence base for decisions about which medicines, vaccines, and health interventions represent good value for money — a vital question for any health system, but especially for Ethiopia where healthcare resources are finite and the burden of disease is high.
Pharmacoeconomics applies economic principles to pharmaceutical products, examining not just the price of a medicine but its full cost-effectiveness relative to alternatives. This discipline underpins rational pharmaceutical pricing policy, formulary decisions, and reimbursement frameworks.
The chapter builds Ethiopian capacity in cost-effectiveness modelling, cost-of-illness studies, budget impact analysis, and value-based pricing — all grounded in the Ethiopian health system context.
The chapter delivered a short course on risk-sharing agreements — a key pharmacoeconomic tool linking medicines reimbursement to real-world outcomes evidence.
Planned workshops on pharmaceutical pricing and market-access frameworks for the Ethiopian context — equipping practitioners to engage with pricing policy.
Supporting members to develop and publish cost-effectiveness models and pharmacoeconomic analyses relevant to the Ethiopian health system, in collaboration with CORE.
Join the chapter for access to training, research opportunities, and a community of practice.